Treatment
BTK inhibitor clinical trials
We’re tracking 11 recruiting studies that include BTK inhibitor, each written for real people, not researchers, below.
Recruiting studies
- NCT06104566RecruitingPhase 3
Study of APG2575 for CLL or SLL patients on BTKi
This trial tests a new drug called APG2575 for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have been taking a BTK inhibitor for at least 12 months. The goal is to see if adding APG2575 can help control the disease better.
Tuscon, ArizonaAges 18–99 - NCT06675123RecruitingPhase 1
Pacritinib with a BTK inhibitor for mantle cell lymphoma
This trial tests a new combination of two targeted drugs (pacritinib plus a BTK inhibitor like ibrutinib) for people with mantle cell lymphoma that has come back or stopped responding to treatment. It may help if your current BTK inhibitor is no longer working well.
Duarte, CaliforniaAges 18 years+ - NCT07416890RecruitingPhase 2
Study of thiotepa, pirtobrutinib, and sintilimab for CNS lymphoma
This trial tests a combination of three drugs for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment, or for those who cannot take standard chemotherapy. The goal is to see if this new combination is safe and effective.
Hangzhou, ZhejiangAges 18–80 - NCT05506410Recruiting
Newly diagnosed mantle cell lymphoma study with Hanlikang and BTK drugs
This trial studies how well Hanlikang and a BTK inhibitor work for people newly diagnosed with mantle cell lymphoma. The goal is to improve lymphoma control while checking safety, since you must meet specific blood, organ, and health requirements.
Zhengzhou, HenanAges 18–90 - NCT06508684Recruiting
BTK inhibitor therapy for CLL/SLL in China
This study looks at how BTK inhibitors (a targeted therapy) are currently used in China for people with CLL or SLL. It aims to understand real-world treatment patterns and outcomes.
Nanjin, JiangsuAges 18–80 - NCT05724121Recruiting
Study heart rhythm changes during BTK or venetoclax treatment
This observational study tracks how your heart rhythm (heartbeat pattern) changes while you take a BTK inhibitor or venetoclax. It may help doctors better understand heart rhythm risks in people receiving these cancer-related medicines.
Bethesda, MarylandAges 18–110 - NCT05833763RecruitingPhase 2
Glosfitamab plus pirtobrutinib for mantle cell lymphoma after BTK drugs
This Phase 2 trial tests how well two anti-cancer medicines—glofitamab and pirtobrutinib—work for mantle cell lymphoma (MCL) that has not responded well to prior BTK inhibitor therapy. It may help by shrinking the lymphoma after earlier treatment and checking how safe the combination is for people with similar disease history.
Parkville, VictoriaAges 18 years+ - NCT06958705RecruitingPhase 2
Testing venetoclax after BTK inhibitor for CLL
This trial tests giving venetoclax to people with CLL who are already taking a BTK inhibitor and have stable disease. The goal is to see if adding venetoclax can help eliminate any remaining CLL cells.
Nanjing, JiangsuAges 18–80 - NCT07377578RecruitingPhase 3
Rocbrutinib vs other BTK inhibitors for mantle cell lymphoma
This study tests a new targeted therapy called Rocbrutinib against other BTK inhibitors for people with mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see which works better and how safe they are.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06211413Enrolling by invitation
Tracking heart issues in CLL patients on BTK inhibitors
This study watches for high blood pressure and irregular heartbeats in people with CLL who are starting a type of targeted therapy called a BTK inhibitor (acalabrutinib or zanubrutinib). Researchers will use a smartwatch and blood pressure cuff to monitor your heart health at home.
Philadelphia, PennsylvaniaAges 22 years+ - NCT06846671RecruitingPhase 3
Study of a new drug for CLL or SLL
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
Jonesboro, ArkansasAges 18 years+
What BTK inhibitor is being studied for
Conditions with recruiting BTK inhibitor studies.
Common questions
- Are there clinical trials studying BTK inhibitor?
- Yes. Clin2 currently lists 11 recruiting studies that include BTK inhibitor, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a BTK inhibitor trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is BTK inhibitor an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether BTK inhibitor or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.